Galmed Pharmaceuticals - ADR Peer Comparison
$4.12
$-0.05
(-1.08%)
As on 31-Aug-2026 16:00EDT
Market cap
$4 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.3
Div. Yield
0 %
Edit
| Galmed Pharmaceuticals - ADR | UroGen Pharma (URGN) | Compugen - ADR | Sol-Gel Technologies - ADR | Evogene - ADR | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
4 | 2,132 | 246 | 225 | 9 |
Revenue ($ Mln) |
-- | 189 | 74 | 2 | 1 |
Net Profit ($ Mln) |
-13.44 | -97.64 | 35.19 | -16.34 | -9.07 |
Net Margin (%) |
-- | -51.73 | 47.55 | -910.14 | -694.19 |
RoE (%) |
-90.40 | -- | 36.76 | -46.08 | -- |
Price to Earnings |
-- | -- | 6.84 | -- | -- |
Price-To-Book |
0.32 | 19.27 | 2.95 | 4.94 | 6.18 |
Cashflow ($ Mln)
| Galmed Pharmaceuticals - ADR | UroGen Pharma (URGN) | Compugen - ADR | Sol-Gel Technologies - ADR | Evogene - ADR | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-6.32 | -162.44 | 31.63 | 0.32 | -13.50 |
|
Cash Flow from Investing Activities
|
-3.38 | 61.56 | 30.00 | -8.58 | 17.74 |
|
Cash from Financing Activities
|
9.03 | 39.92 | 10.60 | 0.01 | -6.60 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Galmed Pharmaceuticals - ADR | UroGen Pharma (URGN) | Compugen - ADR | Sol-Gel Technologies - ADR | Evogene - ADR | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-64.21 | -223.36 | 43.23 | -22.71 | -125.34 |
|
ROE (%)
|
-90.40 | 268.63 | 36.76 | -46.08 | 1,106.98 |
|
ROA (%)
|
-46.81 | -34.21 | 24.43 | -21.91 | -24.72 |
|
EBIT Margin (%)
|
-- | -38.55 | 0.00 | 0.00 | -1,029.84 |
|
Net Margin (%)
|
-- | -51.73 | 47.55 | -910.14 | -694.19 |
|
Cash Profit Margin (%)
|
-- | 0.00 | -- | -- | 0.00 |
Growth Ratios
| Galmed Pharmaceuticals - ADR | UroGen Pharma (URGN) | Compugen - ADR | Sol-Gel Technologies - ADR | Evogene - ADR | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | 100.27 | 234.18 | -92.50 | -80.43 |
|
EBIT Growth (%)
|
34.71 | 44.16 | -- | -- | -8.41 |
|
Net Profit Growth (%)
|
-54.07 | 37.00 | 281.73 | -379.09 | 36.34 |
|
EPS Growth (%)
|
10.84 | 40.19 | 276.06 | -424.44 | 59.44 |
|
Book Value Growth (%)
|
-59.29 | -34.36 | 74.49 | 28.50 | 45.11 |
Valuation Ratios
| Galmed Pharmaceuticals - ADR | UroGen Pharma (URGN) | Compugen - ADR | Sol-Gel Technologies - ADR | Evogene - ADR | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-0.48 | -7.51 | 4.10 | -19.16 | -1.13 |
|
Price / Book Value
|
0.31 | -10.93 | 1.41 | 5.15 | -116.95 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
1.28 | -8.56 | 0.06 | -12.71 | 0.10 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Galmed Pharmaceuticals - ADR | UroGen Pharma (URGN) | Compugen - ADR | Sol-Gel Technologies - ADR | Evogene - ADR | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | -1.43 | 0.00 | 0.00 | 0.00 |
|
Short term debt to equity ratio
|
0.00 | -0.02 | 0.01 | 0.01 | -0.20 |
|
Current Ratio
|
7.71 | 3.80 | 5.72 | 10.37 | 3.57 |
|
Quick Ratio
|
7.71 | 3.41 | 5.72 | 10.37 | 3.54 |
|
Interest Coverage
|
-- | -1.84 | -- | -- | -2.21 |
Operating Efficiency Ratios
| Galmed Pharmaceuticals - ADR | UroGen Pharma (URGN) | Compugen - ADR | Sol-Gel Technologies - ADR | Evogene - ADR | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
-- | 47.03 | 5.55 | 39.72 | 29.38 |
|
Asset Turnover
|
0.00 | 0.66 | 0.51 | 0.02 | 0.04 |
|
Receivable days
|
-- | 88.80 | 1.41 | 52.40 | 135.80 |
|
Inventory Days
|
-- | 376.94 | -- | -- | 90.51 |
|
Payable days
|
-- | 338.46 | 82.73 | 3,350.92 | 83.28 |
|
Cash Conversion Cycle
|
-- | 127.29 | -- | -- | 143.02 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
